BridgeBio Pharma, Inc. (BBIO) /
The revenue of BridgeBio Pharma, Inc. over the past 9 years
Chart BridgeBio Pharma, Inc.: revenue, fiscal 2017–2025 Open the chart →BridgeBio Pharma, Inc. reported revenue of $502.08M in fiscal 2025, the latest fiscal year on file. In fiscal 2019 it was $40.56M — up 1138% over 6 years. Year over year, revenue rose 4 times and fell twice. In these years the lowest $8.25M in fiscal 2020. The largest one-year move was in fiscal 2024: up 2285%, from $9.3M to $221.9M.
Year by year
| Fiscal year | Revenue |
|---|---|
| 2025ended Dec 31, 2025 | $502.08M |
| 2024ended Dec 31, 2024 | $221.9M |
| 2023ended Dec 31, 2023 | $9.3M |
| 2022ended Dec 31, 2022 | $77.65M |
| 2021ended Dec 31, 2021 | $69.72M |
| 2020ended Dec 31, 2020 | $8.25M |
| 2019ended Dec 31, 2019 | $40.56M |
| 2018ended Dec 31, 2018 | — |
| 2017ended Dec 31, 2017 | — |
Fiscal years as BridgeBio Pharma, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on BridgeBio Pharma, Inc.
- The profitability of BridgeBio Pharma, Inc.
- The cash flow of BridgeBio Pharma, Inc.
- The debt of BridgeBio Pharma, Inc.
- All of BridgeBio Pharma, Inc.'s financials, charted
Companies of a similar size
- TXTTextron Inc.
- ARCCAres Capital Corp
- LSCCLATTICE SEMICONDUCTOR CORP
- DOCHealthpeak Properties, Inc.
- MTZMASTEC INC
Not investment advice. This page shows what BridgeBio Pharma, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.